Blood Proteins in Small Vesicles to Spot Diabetes Risk in Obesity
Tests blood proteins in small vesicles to find adults with obesity at risk.
Key facts
- Who runs it
- Hong Kong Baptist University
- Where
- Kowloon Tong, Hong KongSee the siteAlso in 1 other country, 1 site
- Trial code
- Registry title
- Blood-based sEV Proteins for Early Detection of 2 Diabetes
- Status
- Not yet recruiting
- People taking part
- 120 people, planned
- Started
- Oct 2026
- Expected to end
- Dec 2028
- Type of study
- Observational, 4 groups
- Record updated
- 30 July 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for Hong Kong citizens aged 40 to 59 years who agree to a BMI check and a fasting blood draw. It studies blood proteins that may show early risk of type 2 diabetes in people with obesity.
- Age
- 40 to 59 years
- Sex
- Men and women can join.
Main reasons for not taking part
- Cardiovascular disease
- Cancer
- Infectious disease
- Pregnancy, suspected pregnancy or breastfeeding
- History of surgery, as specified in the study protocol
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- Hong Kong citizens
- Male or female
- Aged 40-59 years
- Able and willing to provide written informed consent
- Willing to undergo BMI assessment and fasting blood collection after an overnight fast of at least 8 hours
Who cannot take part
- Cardiovascular disease
- Cancer
- History of surgery, as specified in the study protocol
- Infectious disease
- Genetic disease
- Osteoarthritis
- Pregnancy or breastfeeding
- Suspected pregnancy
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 59 years old?
Where in Hong Kong
Also in 1 other country, 1 site
- Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice CentreKowloon Tong, Hong KongContact: Kam Wa ChanNot yet recruiting
About the trial
What the trial wants to find out
The prevalence of diabetes in China is a significant concern. In 2019, 116.4 million adults were living with diabetes, a number expected to climb to 147.2 million by 2045. Type 2 diabetes (T2D) constitutes 95% of these cases . In Hong Kong, T2D affects an estimated 700,000 people, with prevalence keeps rising. Epidemiology data clearly show that obesity and T2D are closely associated. A previous study conducted by the investigators found that integrin-β2 protein levels are significantly increased in the circulating small extracellular vesicles (sEVs) of obese/overweight individuals.
Read full original descriptionShow less
Given the well-known association between integrin/ECM and the development of insulin resistance, The study hypothesis is that integrin-β2 and ECM1 proteins in the circulating sEVs can be used for the early detection of obese individuals at risk for T2D.This proposed study is critical to provide supporting data for the implementation of a subsequent prospective cohort study to validate whether integrin β2/ECM1 proteins in circulating sEVs can be used for the early detection of obese individuals at risk for T2D.
The 4 groups in the trial
- Normal Weight Without Prediabetes or T2D
Participants with a BMI of 18.8 to 22.9 who do not meet the study criteria for prediabetes or type 2 diabetes.
- Overweight or Obesity Without Prediabetes or T2D
Participants who are overweight or obese, with a BMI of 23.0 or higher, and who do not meet the study criteria for prediabetes or type 2 diabetes
- Normal Weight With Prediabetes or T2D
Participants with a BMI of 18.8 to 22.9, who meet the study criteria for prediabetes or type 2 diabetes based on fasting plasma glucose and HbA1c measurements.
- Overweight or Obesity With Prediabetes or T2D
Participants who are overweight or obese, with a BMI of 23.0 or higher, and who meet the study criteria for prediabetes or type 2 diabetes based on fasting plasma glucose and HbA1c measurements.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Identification of Blood-based sEV Proteins for Early Detection of At-risk Obese Individuals for Type 2 Diabetes
- Plain-language title
- Blood Proteins in Small Vesicles to Spot Diabetes Risk in ObesityGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT07728591, who can take part
- Record updated
- 30 July 2026